Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 607Lung Neoplasms 190Mesothelioma, Malignant 46Adenocarcinoma of Lung 42Mesothelioma 40Neoplasms 31Neoplasm Metastasis 28Carcinoma 18Colorectal Neoplasms 16Small Cell Lung Carcinoma 14Parkinson Disease 4, Autosomal Dominant Lewy Body 14NSCLC 14Adenocarcinoma 11Melanoma 10Lung Diseases 10Brain Neoplasms 10Adenocarcinoma, Bronchiolo-Alveolar 9Thoracic Neoplasms 8Non-squamous Non-small Cell Lung Cancer 8Carcinoma, Bronchogenic 8Respiratory Tract Neoplasms 7Non-Squamous Non-Small Cell Lung Cancer 7Neoplasms by Site 7Bronchial Neoplasms 7Respiratory Tract Diseases 6Ovarian Neoplasms 6Neoplasms by Histologic Type 6Meningeal Carcinomatosis 6Squamous Cell Carcinoma of Head and Neck 5Solitary Fibrous Tumor, Pleural 5

Interventions

Platinum Compounds 2Paclitaxel 2Cisplatin 2Carboplatin 2sintilimab 1osimertinib 1cemiplimab 1Surgical Procedures, Operative 1Pemetrexed 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Resectable Non-small Cell Lung Cancer × Pemetrexed × Thoracic × Clear all
NCT06161441 2026-05-28

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

Regeneron Pharmaceuticals

Phase 2 Active not recruiting
195 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡